149 related articles for article (PubMed ID: 28914627)
1. Antinociceptive effects of JWH015 in female and male rats.
Craft RM; Greene NZ; Wakley AA
Behav Pharmacol; 2018 Apr; 29(2 and 3-Spec Issue):280-289. PubMed ID: 28914627
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ(9)-tetrahydrocannabinol in the rat.
Craft RM; Kandasamy R; Davis SM
Pain; 2013 Sep; 154(9):1709-1717. PubMed ID: 23707295
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid CB
Li AL; Carey LM; Mackie K; Hohmann AG
J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
[TBL] [Abstract][Full Text] [Related]
5. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
6. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
7. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
8. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor 2‑selective agonist JWH015 attenuates bone cancer pain through the amelioration of impaired autophagy flux induced by inflammatory mediators in the spinal cord.
Mao Y; Huang Y; Zhang Y; Wang C; Wu H; Tian X; Liu Y; Hou B; Liang Y; Rong H; Gu X; Ma Z
Mol Med Rep; 2019 Dec; 20(6):5100-5110. PubMed ID: 31661120
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal injection of JWH015 attenuates remifentanil-induced postoperative hyperalgesia by inhibiting activation of spinal glia in a rat model.
Sun Y; Zhang W; Liu Y; Liu X; Ma Z; Gu X
Anesth Analg; 2014 Apr; 118(4):841-53. PubMed ID: 24651239
[TBL] [Abstract][Full Text] [Related]
11. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.
Rahn EJ; Thakur GA; Wood JA; Zvonok AM; Makriyannis A; Hohmann AG
Pharmacol Biochem Behav; 2011 Jun; 98(4):493-502. PubMed ID: 21382397
[TBL] [Abstract][Full Text] [Related]
13. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
14. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility.
Zhong L; Geng L; Njie Y; Feng W; Song ZH
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):1988-92. PubMed ID: 15914613
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.
Burgos E; Pascual D; Martín MI; Goicoechea C
Eur J Pain; 2010 Jan; 14(1):40-8. PubMed ID: 19318283
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats.
Sagar DR; Kelly S; Millns PJ; O'Shaughnessey CT; Kendall DA; Chapman V
Eur J Neurosci; 2005 Jul; 22(2):371-9. PubMed ID: 16045490
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
18. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
19. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal administration of the cannabinoid 2 receptor agonist JWH015 can attenuate cancer pain and decrease mRNA expression of the 2B subunit of N-methyl-D-aspartic acid.
Gu X; Mei F; Liu Y; Zhang R; Zhang J; Ma Z
Anesth Analg; 2011 Aug; 113(2):405-11. PubMed ID: 21519057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
